Conduction System Pacing Shows Superiority Over Biventricular Pacing in Heart FailureConduction system pacing shows better results for heart failure patients

This meta-analysis evaluates the efficacy of conduction system pacing (CSP)—including left bundle branch pacing, his bundle pacing, and optimized CRT—compared to traditional biventricular (BiV) pacing in patients requiring cardiac resynchronization therapy. By analyzing a large cohort of 5,524 patients, the study aims to determine if targeting the heart's intrinsic conduction system provides superior physiological and clinical outcomes for those with heart failure.

The primary outcome, CRT response, showed a statistically significant advantage for CSP over BiV pacing (OR 1.69; 95% CI 1.20-2.39; P =.0027). This suggests that by utilizing the heart's natural electrical pathways, patients may achieve better synchronization and physiological integration than with standard biventricular pacing techniques.

Clinical outcomes also favored the CSP intervention. The data revealed a significantly higher odds of clinical response (OR 1.83; 95% CI 1.12-2.99; P =.01). Furthermore, patients receiving CSP demonstrated a lower risk of composite outcomes (OR 0.51; 95% CI 0.30-0.88; P =.01), indicating a broader range of improved clinical markers compared to the standard of care.

Mortality and hospitalization metrics further support the adoption of CSP. The analysis showed a significant reduction in the odds of heart failure hospitalization (OR 0.58; 95% CI 0.35-0.96; P =.0347) and a notable decrease in all-cause mortality (OR 0.67; 95% CI 0.46-0.97; P =.0340). These findings suggest that CSP may provide a more durable and protective effect for patients with advanced heart failure.

Secondary physiological markers also showed significant improvement with CSP. These included reduced QRS duration, improved left ventricular ejection fraction (LVEF), decreased left ventricular end-systolic diameter (LVESD), and lower NT-proBNP levels. Additionally, patients in the CSP group showed improved New York Heart Association (NYHA) classifications and increased 6-minute walk distances (6MWD), reflecting improved functional capacity.

While the Bayesian meta-analysis consistently favored CSP across all clinical outcomes with a probability exceeding 90%, the study notes certain limitations. Specifically, an analysis restricted only to randomized clinical trials (RCTs) yielded inconsistent results for most outcomes except for clinical response. Therefore, while the evidence is promising, the findings are based on a mix of RCTs and propensity-matched studies.

In clinical practice, these results suggest that CSP may offer significant advantages over traditional BiV pacing for patients indicated for CRT. However, clinicians should interpret these findings with the understanding that larger, high-powered randomized clinical trials are still necessary to confirm these benefits and establish CSP as the definitive standard of care for this patient population.